Guardant Health, Inc. (GH) Stock Forecast
GH analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.69 / 5 from 26 analysts
- Price target
- $201.64 average of analyst targets
- Upside to target
- +27.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.62
- 52-week range
- $67.51 – $187.22
GH analyst ratings
26 analystsNumber of analysts at each rating.
GH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.32 | −$0.39 | −$0.22 | −$0.39 | +18.8% | 16 |
| Current fiscal year (2026) | −$1.46 | −$1.81 | −$1.18 | −$1.82 | +19.7% | 21 |
| Next fiscal year (2027) | −$0.41 | −$1.43 | $0.72 | −$1.46 | +72.0% | 19 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $350.7M | $342.4M | $357.0M | +32.2% | 21 |
| Current fiscal year (2026) | $1.36B | $1.35B | $1.40B | +38.4% | 25 |
| Next fiscal year (2027) | $1.84B | $1.72B | $2.03B | +35.1% | 25 |
GH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GH revenue: reported and forecast
GH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.30 | −$0.30 | −$0.31 | −$0.31 | −$0.32 | +5.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.39 | −$1.45 | −$1.46 | −$1.47 | −$1.46 | +4.8% | 0 up · 2 down |
| Next fiscal year (2027) | −$0.43 | −$0.45 | −$0.40 | −$0.41 | −$0.41 | −5.7% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GH beat in 8 of 12.
What analysts expect from GH
26 analysts cover Guardant Health; their consensus rating is strong buy (4.69 on a 1–5 scale, where 5 is a strong buy). The average price target is $201.64, 27.1% above the latest close of $158.60. Analysts expect earnings of −$1.46 per share for 2026, +19.7% from a year earlier. For 2027 the average estimate is −$0.41 per share on revenue of $1.8 billion. Guardant Health beat the EPS estimate in 8 of the last 12 quarters.
Related: GH income statement, GH key metrics, GH chart. See the GH stock overview for the latest quote and news.
GH forecast FAQ
What is Guardant Health's price target?
The average analyst price target for Guardant Health is $201.64, 27.1% above the latest close of $158.60.
Is Guardant Health a buy, hold or sell?
Of 26 analysts covering Guardant Health, 20 rate it a strong buy, 5 a buy, 0 a hold, 1 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Guardant Health's EPS forecast?
Analysts forecast −$1.46 per share for 2026 (range −$1.81 to −$1.18); for 2027 the estimate is −$0.41.
What is Guardant Health's revenue forecast?
The average revenue estimate for 2026 is $1.4 billion, growth of 38.4%; for 2027 it is $1.8 billion.
When does Guardant Health report earnings?
Guardant Health is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.62.
Does Guardant Health usually beat earnings estimates?
Guardant Health reported EPS at or above the analyst estimate in 8 of the last 12 quarters.